ArticleChest2019
Monitoring Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor.
Article in Chest, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 57 citations in OpenAlex.
- Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose-Finding Phase 2 Study.American journal of respiratory and critical care medicine · 2025Trial
- Interventional strategies for pulmonary arterial hypertension: Current perspectives and future directions.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Review
- Reporting changes in right ventricular systolic pressure: insights from Classification and Regression Tree (CART) analysis.Echo research and practice · 2026Article
- Global Resource Disparities Between Pulmonary Hypertension Centers: Results From the International Survey by the PVRI IDDI Access to Care Workstream.Pulmonary circulation · 2026Article
- Drug Development for Pulmonary Arterial Hypertension: Unleashing the Potential of Single-Patient Studies Using Continuous Monitoring.Pulmonary circulation · 2025Article
- Digital Inclusion in a Scottish National Pulmonary Hypertension Population.Pulmonary circulation · 2025Article
- A Word of Caution-Potential Limitations of Pulmonary Artery Pressure Monitoring in Detecting Congestion Caused by Right-Sided Heart Failure.Biomedicines · 2025Article
- Pulmonary Hypertension Care Delivery in the United States: Is It Time to Get with the Guidelines?American journal of respiratory and critical care medicine · 2025Article
- Depression in Pulmonary Hypertension: A Systematic Review of Clinical Outcomes, Treatment Interactions, and Emerging Technologies.Journal of clinical medicine · 2025Review
- Dysfunctional Implantable Pulmonary Artery Sensor Device (CardioMEMS) in Group 2 Pulmonary Hypertension.JACC. Case reports · 2025Article
- Precision Medicine for Pulmonary Vascular Disease: The Future Is Now (2023 Grover Conference Series).Pulmonary circulation · 2025Article
- Risk stratification and treatment goals in pulmonary arterial hypertension.The European respiratory journal · 2024Review
- Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension.The European respiratory journal · 2024Review
- Exploring the patient perspective in pulmonary hypertension.The European respiratory journal · 2024Article
- Cancer Therapy-Associated Pulmonary Hypertension and Right Ventricular Dysfunction: Etiologies and Prognostic Implications.Reviews in cardiovascular medicine · 2024Review
- Pulmonary hypertension secondary to valvular heart disease: a state-of-the-art review.Heart failure reviews · 2024Review
- CS1, a controlled-release formulation of valproic acid, for the treatment of patients with pulmonary arterial hypertension: Rationale and design of a Phase 2 clinical trial.Pulmonary circulation · 2024Article
- Article
- Medical Management of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension.Current heart failure reports · 2023Review
- Evolution and optimization of clinical trial endpoints and design in pulmonary arterial hypertension.Pulmonary circulation · 2023Review
Corrections and comments
- Commented on by
Authors and funding
16 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundPulmonary arterial hypertension (PAH) is a chronic disease that ultimately progresses to right-sided heart failure (HF) and death. Close monitoring of pulmonary artery pressure (PAP) and right ventricular (RV) function allows clinicians to appropriately guide therapy. However, the burden of commonly used methods to assess RV hemodynamics, such as right heart catheterization, precludes frequent monitoring. The CardioMEMS HF System (Abbott) is an ambulatory implantable hemodynamic monitor, previously only used in patients with New York Heart Association (NYHA) class III HF. In this study, we evaluate the feasibility and early safety of monitoring patients with PAH and right-sided HF using the CardioMEMS HF System.
methodsThe CardioMEMS HF sensors were implanted in 26 patients with PAH with NYHA class III or IV right-sided HF (51.3 ± 18.3 years of age, 92% women, 81% NYHA class III). PAH therapy was tracked using a minimum of weekly reviews of CardioMEMS HF daily hemodynamic measurements. Safety, functional response, and hemodynamic response were tracked up to 4 years with in-clinic follow-ups.
resultsThe CardioMEMS HF System was safely used to monitor PAH therapy, with no device-related serious adverse events observed and a single preimplant serious adverse event. Significant PAP reduction and cardiac output elevation were observed as early as 1 month postimplant using trends of CardioMEMS HF data, coupled with significant NYHA class and quality of life improvements within 1 year.
conclusionsThe CardioMEMS HF System provided useful information to monitor PAH therapy, and demonstrated short- and long-term safety. Larger clinical trials are needed before its widespread use to guide therapy in patients with severe PAH with right-sided HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.